UBS analyst Harry Sephton downgraded Sandoz (SDZNY) to Neutral from Buy with a price target of CHF 44, up from CHF 39.50. The firm cites valuation for the downgrade following the stock’s year-to-date rally. It believes Sandoz’s catalyst path in 2025 now well understood.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SDZNY:
- Sandoz price target raised to CHF 41 from CHF 39 at Berenberg
- FDA adds boxed warning to Teva’s Copaxone for allergic reaction
- M&A News: Intra-Cellular Stock Rallies 36% on News of $14.6B Acquisition by Johnson & Johnson
- Intra-Cellular price target raised to $118 from $100 at BofA
- Venu Sports JV discontinued, Walgreens reports Q1 beat: Morning Buzz